We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Dade Behring's Sales Rise in First Quarter

By Labmedica staff writers
Posted on 20 Apr 2001
For the first quarter of 2001, sales rose 13% over sales in the same period in 2000, reports Dade Behring (Deerfield, IL, USA). More...
These results include a favorable one-time impact resulting from the company's adoption of a new accounting standard. Excluding this impact, sales were still up 7%. The growth was attributed to increased sales of the company's Dimension system and specialty product lines.

For the full year 2000, however, revenues were US$1.184 billion, about a 10% decrease from 1999. Dade Behring says revenues were affected by rising interest rates and a falling Euro as well as a decision to insource the distribution of two important product lines, which required a significant short-term use of cash.

"We are continuing to take aggressive, well-considered steps to address our financial performance, which was disappointing in 2000,” said Jim Reid-Anderson, president and CEO. "Already, we have eliminated several layers of management, consolidated support areas, and completed a significant global restructuring. These actions are generating encouraging results, and we are seeing revenue and earnings growth versus both our current financial plan and prior year in the first quarter of 2001.”


Related Links:
Dade Behring

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.